A Not-So-Little Role for Lipoprotein(a) in the Development of Calcific Aortic Valve Disease.
作者信息
Rogers Maximillian A, Aikawa Elena
机构信息
From Center for Interdisciplinary Cardiovascular Sciences (M.A.R., E.A.) and Center for Excellence in Vascular Biology (E.A.), Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
出版信息
Circulation. 2015 Aug 25;132(8):621-3. doi: 10.1161/CIRCULATIONAHA.115.018139. Epub 2015 Jul 29.
Abstract
摘要
相似文献
1
A Not-So-Little Role for Lipoprotein(a) in the Development of Calcific Aortic Valve Disease.脂蛋白(a)在钙化性主动脉瓣疾病发展中的一个不小的作用。
Circulation. 2015 Aug 25;132(8):621-3. doi: 10.1161/CIRCULATIONAHA.115.018139. Epub 2015 Jul 29.
2
Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve.脂蛋白(a)衍生的自分泌酶和瓣间充质细胞促进主动脉瓣炎症和钙化。
Circulation. 2015 Aug 25;132(8):677-90. doi: 10.1161/CIRCULATIONAHA.115.016757. Epub 2015 Jul 29.
3
Pathobiology of Lp(a) in calcific aortic valve disease.脂蛋白（a）在钙化性主动脉瓣疾病中的病理生物学。
Expert Rev Cardiovasc Ther. 2017 Oct;15(10):797-807. doi: 10.1080/14779072.2017.1367286. Epub 2017 Aug 24.
4
Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study.前蛋白转化酶枯草杆菌蛋白酶/kexin 9型水平与主动脉瓣钙化：一项前瞻性横断面研究。
J Int Med Res. 2016 Aug;44(4):865-74. doi: 10.1177/0300060516648030. Epub 2016 Jun 8.
5
6
Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis.骨唾液蛋白和骨形态发生蛋白-2在钙化性主动脉瓣狭窄中的表达
J Heart Valve Dis. 2004 Jul;13(4):560-6.
7
Transcription factor Egr-1 in calcific aortic valve disease.转录因子Egr-1在钙化性主动脉瓣疾病中的作用
J Heart Valve Dis. 2004 Nov;13(6):894-903.
8
Increased expression of cystatin C and transforming growth factor β-1 in calcific aortic valves.胱抑素C和转化生长因子β-1在钙化主动脉瓣中的表达增加。
Int J Cardiol. 2014 Oct 20;176(3):1252-4. doi: 10.1016/j.ijcard.2014.07.199. Epub 2014 Aug 4.
9
Cadherin-11 Overexpression Induces Extracellular Matrix Remodeling and Calcification in Mature Aortic Valves.钙黏蛋白-11过表达诱导成熟主动脉瓣细胞外基质重塑和钙化。
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1627-37. doi: 10.1161/ATVBAHA.116.307812. Epub 2016 Jun 16.
10
Tumor necrosis factor-α accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway.肿瘤坏死因子-α通过 BMP2-Dlx5 通路加速了从钙化性主动脉瓣狭窄患者获得的人主动脉瓣间质细胞的钙化。
J Pharmacol Exp Ther. 2011 Apr;337(1):16-23. doi: 10.1124/jpet.110.177915. Epub 2010 Dec 30.
引用本文的文献
1
Lipoprotein(a)'s Role in Atherosclerosis and Aortic Stenosis: A Contemporary Literature Review.脂蛋白(a)在动脉粥样硬化和主动脉狭窄中的作用：当代文献综述
Cureus. 2024 Jun 23;16(6):e62984. doi: 10.7759/cureus.62984. eCollection 2024 Jun.
2
Impact of Elevated Lipoprotein A on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.脂蛋白A升高对接受经皮冠状动脉介入治疗患者临床结局的影响：一项系统评价和荟萃分析
Cureus. 2024 May 25;16(5):e61069. doi: 10.7759/cureus.61069. eCollection 2024 May.
3
High lipoprotein(a): Actionable strategies for risk assessment and mitigation.高脂蛋白(a)：风险评估与缓解的可行策略
Am J Prev Cardiol. 2024 Apr 3;18:100651. doi: 10.1016/j.ajpc.2024.100651. eCollection 2024 Jun.
4
The Relationship Between Endocan and Serum Inflammatory Markers in Patients with Senile Calcific Aortic Stenosis.老年钙化性主动脉瓣狭窄患者体内内源性血管生成素与血清炎症标志物的关系
Anatol J Cardiol. 2024 Jan 7;28(2):102-8. doi: 10.14744/AnatolJCardiol.2023.3695.
5
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in aortic stenosis - Is this the light at the end of the tunnel for patients with aortic stenosis?前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂在主动脉瓣狭窄中的应用——这是否是主动脉瓣狭窄患者的一线曙光？
Indian Heart J. 2021 Mar-Apr;73(2):249-252. doi: 10.1016/j.ihj.2021.01.017. Epub 2021 Jan 16.
6
Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.脂蛋白(a)：心血管疾病和急性心肌梗死的一个独立、遗传且具有因果关系的因素。
Indian Heart J. 2019 Mar-Apr;71(2):99-112. doi: 10.1016/j.ihj.2019.03.004. Epub 2019 Mar 20.
7
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.脂蛋白(a)作为动脉粥样硬化性心血管疾病的一个古老和新的因果风险因素。
J Atheroscler Thromb. 2019 Jul 1;26(7):583-591. doi: 10.5551/jat.RV17034. Epub 2019 Apr 30.
8
Advances in Pathophysiology of Calcific Aortic Valve Disease Propose Novel Molecular Therapeutic Targets.钙化性主动脉瓣疾病的病理生理学进展提出了新的分子治疗靶点。
Front Cardiovasc Med. 2018 Mar 14;5:21. doi: 10.3389/fcvm.2018.00021. eCollection 2018.
9
Creation of disease-inspired biomaterial environments to mimic pathological events in early calcific aortic valve disease.创建疾病启发型生物材料环境，以模拟早期钙化性主动脉瓣疾病中的病理事件。
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E363-E371. doi: 10.1073/pnas.1704637115. Epub 2017 Dec 27.
10
Calcific aortic stenosis.钙化性主动脉瓣狭窄。
Nat Rev Dis Primers. 2016 Mar 3;2:16006. doi: 10.1038/nrdp.2016.6.
本文引用的文献
1
Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve.脂蛋白(a)衍生的自分泌酶和瓣间充质细胞促进主动脉瓣炎症和钙化。
Circulation. 2015 Aug 25;132(8):677-90. doi: 10.1161/CIRCULATIONAHA.115.016757. Epub 2015 Jul 29.
2
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.阿利西尤单抗降低血脂和心血管事件的疗效和安全性。
N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.
3
Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability.具有重大影响的小实体：微钙化与动脉粥样硬化斑块易损性
Curr Opin Lipidol. 2014 Oct;25(5):327-32. doi: 10.1097/MOL.0000000000000105.
4
Potential drug targets for calcific aortic valve disease.钙化性主动脉瓣疾病的潜在药物靶点。
Nat Rev Cardiol. 2014 Apr;11(4):218-31. doi: 10.1038/nrcardio.2014.1. Epub 2014 Jan 21.
5
Heart disease and stroke statistics--2014 update: a report from the American Heart Association.《2014年心脏病和中风统计数据更新：美国心脏协会报告》
Circulation. 2014 Jan 21;129(3):e28-e292. doi: 10.1161/01.cir.0000441139.02102.80. Epub 2013 Dec 18.
6
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).脂蛋白(a)浓度、瑞舒伐他汀治疗与残余血管风险：来自 JUPITER 试验（他汀类药物预防的理由：评估瑞舒伐他汀的干预试验）的分析。
Circulation. 2014 Feb 11;129(6):635-42. doi: 10.1161/CIRCULATIONAHA.113.004406. Epub 2013 Nov 17.
7
Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.脂蛋白(a)水平升高与普通人群主动脉瓣狭窄的风险。
J Am Coll Cardiol. 2014 Feb 11;63(5):470-7. doi: 10.1016/j.jacc.2013.09.038. Epub 2013 Oct 23.
8
Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization.脂蛋白相关磷脂酶 A2 在钙化性主动脉瓣疾病中的高表达：对瓣膜矿化的影响。
J Am Coll Cardiol. 2014 Feb 11;63(5):460-9. doi: 10.1016/j.jacc.2013.05.105. Epub 2013 Oct 23.
9
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.AMG145，一种针对前蛋白转化酶枯草溶菌素 9 的单克隆抗体，可显著降低接受他汀类药物治疗的高胆固醇血症患者的脂蛋白(a)：来自 LDL-C 评估与前蛋白转化酶枯草溶菌素 9 单克隆抗体抑制联合他汀类药物治疗（LAPLACE）-心肌梗死溶栓治疗（TIMI）57 试验的分析。
Circulation. 2013 Aug 27;128(9):962-9. doi: 10.1161/CIRCULATIONAHA.113.001969. Epub 2013 Jul 24.
10
Scavenger receptor-BI is a receptor for lipoprotein(a).清道夫受体-BI 是脂蛋白(a)的受体。
J Lipid Res. 2013 Sep;54(9):2450-7. doi: 10.1194/jlr.M038877. Epub 2013 Jun 29.
Zotero 插件